Back to Search Start Over

Single Institution Experience with Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for the Primary Prevention of Lymphedema

Authors :
P Ananthakrishnan
Christine H. Rohde
Robert T Grant
David Leung
Peter W. Henderson
Chaitanya R. Divgi
Margaret Chen
Bret Taback
Amiya Vaz
Billie Borden
Adewuni Ojo
Sheldon Feldman
Hannah Bansil
Fatih Levent Balci
Jeffrey A. Ascherman
Source :
Annals of Surgical Oncology. 22:3296-3301
Publication Year :
2015
Publisher :
Springer Science and Business Media LLC, 2015.

Abstract

As many as 40 % of breast cancer patients undergoing axillary lymph node dissection (ALND) and radiotherapy develop lymphedema. We report our experience performing lymphatic–venous anastomosis using the lymphatic microsurgical preventive healing approach (LYMPHA) at the time of ALND. This technique was described by Boccardo, Campisi in 2009. LYMPHA was offered to node-positive women with breast cancer requiring ALND. Afferent lymphatic vessels, identified by injection of blue dye in the ipsilateral arm, were sutured into a branch of the axillary vein distal to a competent valve. Follow-up was with pre- and postoperative lymphoscintigraphy, arm measurements, and (L-Dex®) bioimpedance spectroscopy. Over 26 months, 37 women underwent attempted LYMPHA, with successful completion in 27. Unsuccessful attempts were due to lack of a suitable vein (n = 3) and lymphatic (n = 5) or extensive axillary disease (n = 1). There were no LYMPHA-related complications. Mean follow-up time was 6 months (range 3–24 months). Among completed patients, 10 (37 %) had a body mass index of ≥30 kg/m2 (mean 27.9 ± 6.8 kg/m2, range 17.4–47.6 kg/m2), and 17 (63 %) received axillary radiotherapy. Excluding two patients with preoperative lymphedema and those with less than 3-month follow-up, the lymphedema rate was 3 (12.5 %) of 24 in successfully completed and 4 (50 %) of 8 in unsuccessfully treated patients. Our transient lymphedema rate in this high-risk cohort of patients was 12.5 %. Early data show that LYMPHA is feasible, safe, and effective for the primary prevention of breast cancer-related lymphedema.

Details

ISSN :
15344681 and 10689265
Volume :
22
Database :
OpenAIRE
Journal :
Annals of Surgical Oncology
Accession number :
edsair.doi.dedup.....a2baf3c0a75ea969a7e4d09028eec3b9
Full Text :
https://doi.org/10.1245/s10434-015-4721-y